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Abstract

Introduction

Idiopathic non-cirrhotic portal hypertension (INCPH) is a clinicopathologic disease entity characterized by the presence of clinical
signs and symptoms of portal hypertension (PH) in the absence of
liver cirrhosis or known risk factors accountable for PH. Multiple
hematologic, immune-related, infectious, hereditary and metabolic
risk factors have been associated with this disorder. Still, the exact
etiopathogenesis is largely unknown. The recently proposed portosinusoidal vascular disease (PSVD) scheme broadens the spectrum
of the disease by also including patients without clinical PH who
are found to have similar histopathologic findings on core liver
biopsies. Three histomorphologic lesions have been identified as
specific for PSVD to include obliterative portal venopathy, nodular regenerative hyperplasia and incomplete septal cirrhosis/fibrosis. However, these findings are often subtle, under-recognized and
subjective with low interobserver agreement among pathologists.
Additionally, the natural history of the subclinical forms of the
disease remains unexplored. The clinical course is more favorable
compared to cirrhosis patients, especially in the absence of clinical
PH or liver dysfunction. There are no universally accepted guidelines in regard to diagnosis and treatment of INCPH/PSVD. Hence,
this review emphasizes the need to raise awareness of this entity
by highlighting its complex pathophysiology and clinicopathologic
associations. Lastly, formulation of standardized diagnostic criteria
with clinical validation is necessary to avoid misclassifying vascular diseases of the liver and to develop and implement targeted
therapeutic strategies.

Idiopathic non-cirrhotic portal hypertension (INCPH) is a clinicopathologic disease entity wherein the patient presents with
portal hypertension (PH) without cirrhosis or underlying liver
disease (chronic viral hepatitis, fatty liver disease, autoimmune hepatitis, hereditary hemochromatosis, primary biliary
cholangitis, congenital hepatic fibrosis, sarcoidosis, schistosomiasis, etc.) that can cause PH [1]. Over the past decade, there
has been a growing recognition among gastroenterologists,
hepatologists and pathologists that the histologic findings of
INCPH are not entirely specific to those with PH, and similar
changes can be found in patients without PH. Thus, the novel
entity “porto-sinusoidal vascular disease (PSVD)” has been
introduced to broaden the definitional spectrum of INCPH
and capture pre-PH phase of INCPH as well as INCPH that is
concurrent with other liver diseases [2]. Yet, understanding the
concept and clinical significance of PSVD, especially without
PH, remains elusive.
In this review paper, we aim to systematically review the
currently available evidence and enhance our understanding of
INCPH and PSVD. More specifically, we provide an overview
of the definition, terminologies and epidemiology of INCPH/
PSVD and review clinical, radiologic and histologic features
of this rare entity, with emphasis on the evolving pathophysiologic understandings that are currently available. This review
would lay out a solid foundation for future studies of the natural history of PSVD in patients with no PH at the time of diagnosis.
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Background
PH is defined by the presence of an elevated hepatic venous
pressure gradient (HVPG, the difference between free hepatic
venous pressure and wedge hepatic venous pressure) exceeding 5 mm Hg. PH is often the result of increased resistance in
the portal blood outflow tract [1]. Signs of PH include varices,
porto-systemic collaterals, ascites and thrombocytopenia with
splenomegaly (Table 1). Hepatic cirrhosis is the most common
etiology of PH in the Western hemisphere while schistosomiasis is a frequent culprit in endemic areas to include southern
and sub-Saharan Africa, South America, the Caribbean, parts
of China and Southeast Asia [3-5]. The abnormal impedance
to portal venous flow can occur at differing levels, such as the
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Table 1. Symptoms and Signs of Portal Hypertension
Specific signs

Non-specific signs
Ascites, thrombocytopenia, splenomegaly

Clinical

Variceal bleeding, collaterals seen on physical examination

Endoscopic

Varices

Radiographic

Porto-systemic collaterals, increased HVPG

Ascites, splenomegaly

HPVG: hepatic venous pressure gradient.

prehepatic (i.e., portal vein), intrahepatic (involvement of intraparenchymal sinusoids and venules) or post-hepatic (i.e.,
hepatic veins) level. When signs and symptoms of PH develop
in the absence of liver cirrhosis, the condition is designated as
non-cirrhotic portal hypertension (NCPH).
Interestingly, some chronic hepatopathies that ultimately
culminate in the development of cirrhosis can manifest as PH
even before liver cirrhosis develops and qualify for NCPH although admittingly, the terms NCPH and INCPH have been
interchangeably used in the literature [5-7]. This includes alcoholic and nonalcoholic fatty liver disease (NAFLD), metabolic
liver diseases and autoimmune diseases such as primary biliary cholangitis and primary sclerosing cholangitis. Exposure
to medications and toxins, congenital hepatic fibrosis and infiltrative liver diseases (i.e., sarcoidosis) can also be involved in
the pathogenesis of PH without cirrhosis [1, 3, 5].
Yet, some patients present with PH without identifiable
cause including the entities mentioned above. Only after excluding cirrhosis by histologic examination, eliminating a mechanical (i.e., portal vein thrombosis, Budd-Chiari syndrome
(BCS)) or physiologic (i.e., right-sided heart failure) blood
flow obstruction in the portal and hepatic venous systems
clinically and/or radiologically, and confirming the absence of
chronic liver disease or known risk factors for PH, can a diagnosis of INCPH be rendered [1].

INCPH vs. PSVD
INCPH encompasses a heterogenous group of hepatic disorders for which the terminology was first introduced by
Shouten et al in 2011 [1, 8]. Histologic features commonly
seen in INCPH include obliterative portal venopathy (OPV),
nodular regenerative hyperplasia and incomplete septal cirrhosis/fibrosis. Other findings include sinusoidal dilatation, mild
perisinusoidal fibrosis, central vein abnormalities and variable
portal vascular aberrancies (Table 2 [1, 2, 8-11]).
However, to date, this entity remains relatively poorly understood due to varying nomenclature and the lack of standardized diagnostic criteria. Furthermore, even though recent
large-scale morphologic studies and collaborations on this topic [9, 12-14] enabled us to have a better understanding of the
pathogenesis of this entity and recognize the wide histologic
spectrum it displays, several shortcomings still exist.
Firstly, histologic features of INCPH are not entirely specific as they can be seen in liver specimens from patients without PH. Whether this finding represents a pre-PH phase of INCPH is currently unknown and this notion remains somewhat
speculative [12]. For example, portal vascular aberrancies that
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have been described in INCPH were seen in “normal” aging
livers [15] and liver samples from trauma patients [16]. Similarly, portal and lobular vascular changes that can be seen in
INCPH were present in liver biopsies taken during gastric bypass surgery or cholecystectomy [13], in patients with hemochromatosis with or without history of phlebotomy [14] and in
nine (69%) of 13 patients on dialysis [17], all in the absence
of PH. Likewise, in a recent interobserver variability study,
the control group patients without PH who showed some features of INCPH in their liver biopsies did not develop PH after
a mean follow-up of 38 months [18]. In the absence of PH,
these cases would not meet the diagnostic criteria for INCPH.
Therefore, even if some of these indeed were to represent prePH phase of INCPH, we will not be able to diagnose these
patients as having INCPH at the time of liver biopsy. Secondly,
it has been recognized that certain liver conditions that must
be excluded to establish a diagnosis of INCPH (i.e., fatty liver
disease, viral and autoimmune hepatitis, among others) may in
fact coexist with INCPH [2]. In such cases, the restrictive definition of INCPH would exclude these patients from this group.
These conceptual limitations have led the Vascular Liver
Disease Interest Group (VALDIG) to propose a novel entity designed to broaden the whole aspects and spectrum of the disease
in 2019. The term PSVD was introduced as the disease process
primarily affects the hepatic sinusoids and portal venules [2].
However, this new classification is not without its own
share of limitations. It might be too simplistic as it primarily relies on histomorphologic features for diagnosis which
are known to be subtle and often under-recognized. Moreover,
while this classification attempts to broaden its spectrum, it
also excludes certain conditions that may well co-exist with
PSVD from the definitional spectrum.

Nomenclature
Previously, different terminologies have been used for INCPH/
PSVD. Idiopathic portal hypertension [19] and non-cirrhotic
portal fibrosis [20] were commonly used in Eastern countries
(Japan and India, respectively), while the terms “OPV” and
“hepatoportal sclerosis” were endorsed in the Western literature [10]. Other terminologies that have been used for this entity include “benign intrahepatic portal hypertension”, “intrahepatic noncirrhotic portal hypertension”, “noncirrhotic portal
hypertension”, “idiopathic noncirrhotic intrahepatic portal
hypertension”, “partial nodular transformation”, “incomplete
septal cirrhosis” and “nodular regenerative hyperplasia” [1-3,
6, 7, 10, 21]. Table 3 [3, 6, 12, 16, 19-68] summarizes the terminologies used for this entity.
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Table 2. Histologic Features of Idiopathic Non-Cirrhotic Portal Hypertension/Porto-Sinusoidal Vascular Disease and Their Definitions [1, 2, 8-11]
Specific features*
   Obliterative portal venopathy

Wall thickening and fibrosis with luminal narrowing, obliteration and eventual loss of
intrahepatic portal vein branches

   Nodular regenerative hyperplasia

Micronodularity of hepatic parenchyma in the absence of liver fibrosis. Nodules are composed of
hyperplastic central zones and peripheral atrophic hepatic cell plates.

   Incomplete septal fibrosis/cirrhosis

Delicate fibrous septa originating from a portal tract and ending blindly within a hepatic lobule
without clear connection to central veins or other portal tracts

Not specific features*
  Lobular changes
    Sinusoidal dilatation

Sinusoidal lumen wider than one liver cell plate in the absence
of artifactual tearing, usually non-zonal

    Megasinusoids

Severe sinusoidal dilatation with cystic blood lake formation. Some authors
used the term to describe dilated periportal shunting vessels.

    Perisinusoidal fibrosis

Stellate pattern of collagen deposition around hepatic sinusoids highlighted by collagen stain

    Central vein abnormalities

Central vein dilatation, pericentral vein fibrosis, multiplicity of central veins per lobule

   Portal tract changes
    Periportal shunting vessels

Single or multiple thin-walled vascular channels seen outside but in contact with a portal tract

    Herniated portal vein

Portal vein branch, often dilated, abutting the adjacent hepatic parenchyma
at limiting plate without a rim of intervening connective tissue

    Portal tract remnant

Portal tract smaller than twice the diameter of a bile duct, often with an inconspicuous/absent
portal vein branch or herniated portal vein

    Increased arteriole profiles

Arterialized portal venous branches with acquired smooth muscle layer

    Multiplicity of portal veins

Increased number of portal vein branches within a portal tract, also known as angiomatous
transformation

*Specific and not specific features (lesions) are determined by Vascular Liver Disease Interest Group. This categorization is applicable to porto-sinusoidal vascular disease only [2]. Specificity of these histologic lesions is unknown and not defined for idiopathic non-cirrhotic portal hypertension [11].

Definitions
In 2011, Shouten et al defined INCPH as a disease entity characterized by the presence of PH in the absence of hepatic fibrosis/cirrhosis or other factors that may be accountable for the
development of PH [1, 8]. As a result, chronic liver diseases,
portal, splenic and splanchnic venous thrombosis, and BCS
must be first excluded to render the diagnosis [1, 8].
On the other hand, the diagnosis of PSVD requires a core
liver biopsy of sufficient length (≥ 20 mm or with ≥ 10 portal
tracts) with no evidence of cirrhosis and with either a specific
sign of PH (varices, PH related bleeding, porto-systemic collaterals on imaging) or a specific histologic lesion (i.e., OPV,
incomplete septal fibrosis or incomplete septal cirrhosis, nodular regenerative hyperplasia) for PSVD [2]. PSVD can also
be diagnosed when not specific (of note, VALDIG used the
particular term “not specific” in lieu of “nonspecific” in the
manuscript) signs of PH (determined by VALDIG) and not
specific histologic lesions of PSVD (determined by VALDIG)
are present together, as long as a core ≥ 20 mm of non-cirrhotic
liver is demonstrated [2]. As a result, in contrast to the INCPH
scheme, neither the presence of a contributing factor for parenchymal liver disease (i.e., metabolic, viral or alcoholic liver

disease) nor the absence of clinical PH excludes the diagnosis
of PSVD if a specific histologic lesion is present in a non-cirrhotic liver. Additionally, portal vein thrombosis (particularly
when it is not accompanied by cavernoma) does not eliminate
the possibility of PSVD as it was found to be commonly encountered along the natural course of the disease [2].
Nevertheless, some entities are not to be included in the
broad definitional spectrum of PSVD and, when present,
should prompt an alternative diagnosis. Infiltrative liver diseases (i.e., sarcoidosis, malignancies), congenital hepatic fibrosis, schistosomiasis and heart failure must still be ruled out
before diagnosing PSVD. Chronic cholestatic hepatopathies
must also be excluded [2]. The following are conditions that
closely resemble PSVD histologically and clinically, thus need
to be excluded before rendering a PSVD diagnosis.

Alternative Diagnoses Excluded From PSVD
Spectrum Despite Overlapping Histomorphology
BCS
BCS is characterized by the presence of hepatic venous out-
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Table 3. Different Terminologies Used for Idiopathic Non-Cirrhotic Portal Hypertension/Porto-Sinusoidal Vascular Disease
Terminologies

References

Idiopathic portal hypertension

Kobayashi et al (1976) [19], Okuda et al (1982) [22], Nakanuma et al (1989) [23], Saito et al (1993) [24],
Oikawa et al (1998) [25], Yamaguchi et al (1999) [26], Okudaira et al (2002) [27], Tsuneyama et al (2002)
[28], Kogawa et al (2005) [29], Matsutani et al (2005) [30], Chang et al (2009) [31], Seijo et al (2012) [32],
Furuichi et al (2013) [33], Siramolpiwat et al (2014) [34], Kotani et al (2015) [35]

Non-cirrhotic portal fibrosis

Sarin et al (1987) [36], Mukta et al (2017) [20], Sood et al (2017) [37]

Obliterative portal venopathy

Mikkelsen et al (1965) [38], Nayak et al (1969) [39], Cazals-Hatem et al (2011) [40], Glatard et al (2012)
[41], Aggarwal et al (2013) [42], Franchi-Abella et al (2014) [43], Arora et al (2015) [44], Guido et al (2016)
[12], Besmond et al (2018) [45]

Hepatoportal sclerosis

Mikkelsen et al (1965) [38], Girard et al (2005) [46], Fiel et al (2007) [47], Krishnan et al (2012) [48]

Benign intrahepatic
portal hypertension

Levison et al (1982) [49]

Intrahepatic non-cirrhotic
portal hypertension

Kingham et al (1981) [50], Krasinskas et al (2005) [6], Eapen et al (2011) [51]

Non-cirrhotic portal
hypertension

Ohbu et al (1994) [52], Nakanuma et al (1996) [16], Rajekar et al (2011) [3], Rajesh et al (2018) [53], Gioia
et al (2018) [54], Nicoara-Farcau et al (2020) [55], Gioia et al (2020) [56]

Idiopathic non-cirrhotic
Hillaire et al (2002) [21], Goel et al (2011) [57]
intrahepatic portal hypertension
Partial nodular transformation

Sherlock et al (1966) [58], Wanless et al (1985) [59]

Nodular regenerative
hyperplasia

Steinert et al (1959) [60], Wanless et al (1990) [61], Radomski et al (2000) [62], Austin et al
(2004) [63], Malamut et al (2008) [64], Leung et al (2009) [65], Jharap et al (2015) [66]

Idiopathic presinusoidal
portal hypertension

Polish et al (1962) [67]

Incomplete septal cirrhosis

Sciot et al (1988) [68]

flow tract obstruction (HVOTO) in the absence of right-sided
heart failure or constrictive pericarditis [69, 70]. The terms
BCS and HVOTO can be used interchangeably. BCS can be
primary when the obstruction in the hepatic venous tract is the
result of a thrombus in the context of a hypercoagulable state
or secondary when it is related to invasion or encasement by
a malignant tumor or an abscess [69]. The obstruction can occur at any level between small intrahepatic veins and the right
atrium including the suprahepatic inferior vena cava.
BCS is usually identified by noninvasive imaging modalities such as Doppler ultrasound, triphasic multidetector
computed tomography (CT) and magnetic resonance imaging
(MRI) [70]. In typical cases, a liver biopsy is not required as
histologic findings fail to show independent prognostic value when adjusted for the model for end-stage liver disease
(MELD) or Child-Pugh scores [71]. Liver biopsy may be
performed when the obstruction is at the level of intrahepatic
small venules thus is not detected on imaging, or when the patient presents with cirrhosis of unknown etiology. The biopsy
shows features of venous outflow obstruction pattern injury,
which is a known histologic mimic of PSVD [72, 73] (Fig.
1). Nevertheless, BCS/HVOTO is mainly a clinical/radiologic
diagnosis and should not be considered a form of PSVD [2].
Sinusoidal obstruction syndrome (SOS)
SOS, previously known as a hepatic veno-occlusive disease
52

Figure 1. (a) Liver biopsy from Budd-Chiari syndrome (BCS) shows
venous outflow obstruction pattern injury with mild centrizonal sinusoidal dilatation and congestion (hematoxylin and eosin (H&E), × 100). (b)
Chronic BCS with extensive sinusoidal dilatation, centrizonal hepatocyte atrophy and dropout and fibrosis. The portal tracts are relatively
spared (H&E, × 100).
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Figure 2. (a) Sinusoidal obstruction syndrome (SOS) associated with oxaliplatin chemotherapy. Marked centrizonal congestion
and sinusoidal widening is noted (hematoxylin and eosin, × 100). (b) Trichrome stain shows perisinusoidal fibrosis (Massontrichrome, × 200).

(VOD), is regarded as a distinct entity that is not within the
spectrum of PSVD. SOS is characterized by sinusoidal endothelial cell damage due to exposure to exogenous toxins that
result in partial or complete occlusion of small intrahepatic
veins [74]. SOS/VOD often occurs as a fatal complication following hematopoietic stem cell transplantation (HSCT), but it
can also be seen after exposure to certain chemotherapeutic/
immunomodulatory agents, in particular thiopurine derivatives [74]. The Seattle and Baltimore diagnostic clinical criteria have been extensively used in the setting of HSCT [75].
However, their applicability in non-HSCT patients is not well
established, necessitating liver biopsy in some clinical settings
[71, 73]. Common histologic findings include centrizonal congestion and fibrosis involving sinusoids and/or central veins
[73] (Fig. 2). Again, these histologic features fall within the
spectrum of venous outflow obstruction pattern injury. Hence,
liver diseases in patients with known history of bone marrow
transplantation are excluded from the definition of PSVD [2].
Non-obstructive sinusoidal dilatation (NOSD)
NOSD has histomorphologic features that are overlapping with
PSVD. NOSD is not universally defined; however, some authors define NOSD as a finding of sinusoidal lumina that are
wider than one liver cell plate and present in multiple lobules
with no artifactual tearing, in the absence of post-sinusoidal outflow block (PSOB) [76, 77]. Its clinical significance is unclear
but the sinusoidal widening should not be explained by infiltration by sickle cells, hemophagocytic histiocytes, neoplasms,
BCS, heart failure or small-for-size syndrome after liver transplantation, all of which feature PSOB. SOS/VOD should also
be excluded even though NOSD can also be associated with
drug exposures, notably oxaliplatin-based chemotherapy [77].
Peliosis
Peliosis is considered a severe form of sinusoidal dilatation

with randomly distributed lobular cystic blood lakes [71]. Sinusoidal dilatation/peliosis are believed to be associated with
an abnormal portal venous blood inflow or may represent a
feature of severe systemic inflammatory reaction syndrome
[77]. Peliosis, however, implicates a complete rupture of the
reticulin framework which is not seen in NOSD [77]. PSVD
may be part of the broader spectrum of sinusoidal dilatation/
peliosis [73].
Congenital porto-systemic shunt (CPS)
CPS represents an abnormal intra- or extrahepatic communication between intestinal/splenic venous blood and systemic circulation bypassing liver parenchyma [78]. Extrahepatic CPS
is referred to as Abernethy malformation and is excluded from
the current definition of PSVD [2].

Epidemiology
It is difficult to estimate the incidence of INCPH/PSVD mainly due to varying/evolving nomenclature and geographic differences regarding the identification and classification of this
disorder. Notably, PSVD encompasses a larger population
compared to INCPH as it also includes patients without clinical PH. Moreover, PSVD was first introduced in 2019, thus the
incidence of PSVD inclusive of those without PH is unknown.
INCPH has been widely recognized in Japan and the Indian subcontinent over the past few decades where it constitutes
approximately 30-40% of PH cases [10, 22, 79]. However, due
to increased awareness of the disease and changes in national
health policy, the incidence of INCPH has dramatically decreased in Japan to a total number of 11 new cases per year [2].
The high incidence of INCPH in India appears to be related to
less favorable socio-economic conditions [20, 80]. In North
America and Europe, INCPH is considered a rare disease as it
accounts for around 3-5% of PH cases [10]. However, its incidence is likely to be higher due to frequent under-recognition
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of this entity and the challenges inherent to the diagnosis and
the interpretation of corresponding liver core biopsies. In fact,
many INCPH patients might have been misdiagnosed as having cryptogenic or autoimmune cirrhosis especially in cases
without previous liver biopsy [6].
Geographic demographic differences are also noted. Patients affected with INCPH skew significantly younger in India and Japan (age ranges of 30 - 49 years and 40 - 59 years,
respectively) when compared to Western countries (age range
50 - 69 years) [2]. While the disease primarily affects women
in Japan (although the gender gap is trending downward), it
shows a male predilection in India, North America and Europe [2, 10]. INCPH has been rarely described in the pediatric
population where it accounts for roughly 4.6% of all causes of
PH [37]. In children, INCPH is more common in males and is
more likely to be associated with an underlying malignancy or
a genetic predisposition compared to adults [43, 45].

Pathophysiology and Etiologic Associations
The pathogenesis of INCPH/PSVD remains largely unknown
but it is believed to be related to the injury to and occlusion of the intrahepatic portal microvasculature leading to
increased resistance to portal blood flow at the presinusoidal
level [7, 79, 81]. In cirrhosis-related PH, the portal venous
bed decreases but the hepatic arterial bed increases leading
to various intrahepatic shunts [82, 83]. In INCPH/PSVD, on
the other hand, both venous and arterial beds diminish in size
and intrahepatic shunts seldom occur [25, 27]. The attenuated
portal venous system along with subsequent phlebosclerosis
results in increased blood pressure in non-stenotic venous
branches [7]. The ensuing abnormal/aberrant intrahepatic
portal vasculature in INCPH has been extensively studied
and classified by Ohbu et al [52]. In this study, a combination of phlebosclerosis of portal venous branches and dilated
periportal sinusoids that are not communicating with the portal venous branches was commonly observed in INCPH and
nodular regenerative hyperplasia. Phlebosclerosis of the portal venous branches was less common in extrahepatic portal
venous obstruction [52].
From a purely histomorphologic standpoint, the “portal tract vasculopathy” scheme by Krazinskas et al brings an
insight on the pathogenesis of INCPH/PSVD. The authors
reported portal vascular abnormalities similar to the ones encountered in INCPH in 88% of native and allograft liver biopsies in the absence of PH and without significant differences
between the two groups [7]. The authors proposed the term
“portal tract vasculopathy” and suggested that portal inflammation might be a potential etiologic factor. In the native liver
group, portal tract vasculopathy was associated with hepatitis
C virus (HCV) infection and increasing fibrosis whereas in the
allograft group, it correlated with the severity of a synchronous acute cellular rejection episode, the presence of previous
rejection episodes and increased time following transplantation [7]. Similar portal changes were described in a Japanese
HCV patient without PH or cirrhosis in a three-dimensional
histologic reconstruction study [84]. These studies suggest that
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portal vascular changes that can be seen in INCPH/PSVD may
be at least in part related to portal inflammation. However, INCPH/PSVD biopsies usually do not demonstrate overt portal
inflammation.
In addition, previous studies and reports have linked INCPH/PSVD to various hematologic, immunologic, infectious
and genetic disease processes [1, 3, 10]. Multiple factors may
coexist and contribute to the pathophysiology of this disease.
Immune dysregulation
Multiple studies have reported an association between INCPH/
PSVD and disorders of immune function including congenital [85] (in particular common variable immunodeficiency
(CVID)) and acquired immunodeficiencies (human immunodeficiency virus (HIV)-related) as well as autoimmune diseases [2, 10]. For example, INCPH has been described in patients with inflammatory bowel diseases, rheumatoid arthritis,
systemic lupus erythematosus, autoimmune hepatitis, scleroderma, Felty’s syndrome and celiac disease among others [10,
24, 28, 29, 40, 63-65, 86]. Seropositivity for antinuclear, antimicrosomal and anti-DNA antibodies has also been reported
[3, 23]. The underlying mechanism of immune-induced injury
to the sinusoidal microvasculature is unclear but it appears to
be related to hyperactivation of intrasinusoidal T lymphocytes
[26, 35].
Hematologic factors
Prothrombotic conditions and hypercoagulable states are frequently encountered in patients diagnosed with INCPH/PSVD
[2, 10, 21, 34]. Some of the histologic features of INCPH, in
particular OPV, may be related to previous or recurrent thromboembolic events [8]. Likewise, INCPH/PSVD is frequently
complicated by portal vein thrombosis [2, 30, 31].
In fact, INCPH/PSVD and chronic portal vein thrombosis
share common etiogenic grounds [87] and they display overlapping histologic features in liver biopsies [9]. Therefore,
it would be very difficult or nearly impossible to distinguish
these two, or determine whether portal vein thrombosis in INCPH/PSVD represents an eventual end result of the disease or
it develops de novo in a completely independent manner [73].
Infectious etiologies
INCPH/PSVD has been reported to correlate with recurrent
intraabdominal infections especially in Eastern countries, although this association remains inconclusive [1, 2]. HIV may
also cause a direct virus-induced damage to the sinusoidal
endothelial cells [88]. Endothelial cell injury may also occur
as a result of prolonged exposure to antiretroviral treatment
[31]. Additionally, HIV-related acquired protein S deficiency
induces a state of hypercoagulability, a known risk factor for
INCPH/PSVD [89]. Given the multitude of abnormalities seen
in this population, the exact relationship between HIV and IN-
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Figure 3. (a) Fatty liver disease without cirrhosis or advanced fibrosis, but with portal hypertension. Zonal steatosis is noted
(hematoxylin and eosin (H&E), × 40). (b) Higher magnification view showing pericentral fibrosis (long arrow) probably secondary
to fatty liver disease, and phlebosclerosis (obliterative portal venopathy, short arrow), possibly secondary to concurrent portosinusoidal vascular disease (H&E, × 100).

CPH/PSVD appears to remain speculative [10].
Hereditary predispositions
Familial clusters of INCPH/PSVD have been reported, many
of which were linked to a specific HLA haplotype (HLA-DR3)
[36]. In familial cases, mutations in KCNN3 and DGUOK genes
have been implicated. These alterations are transmitted in an
autosomal dominant and recessive fashion, respectively [90,
91]. Furthermore, those with certain congenital syndromes and
hereditary diseases are at increased risk of developing INCPH/
PSVD (i.e., Turner syndrome, Adams-Oliver syndrome, phosphomannose isomerase deficiency, cystic fibrosis) [2, 46, 92,
93]. Lastly, HIV patients who harbor specific single nucleotide
polymorphisms (SNPs) in genes encoding the enzymes involved
in purine metabolism are at increased risk of INCPH/PSVD
when exposed to didanosine, an anti-retroviral agent [94].
Drug exposure
Exposure to variable drugs such as azathioprine, oxaliplatin,
stavudine, didanosine and thioguanine has been linked to the
development of INCPH/PSVD [2, 10].
Idiopathic
Some INCPH/PSVD patients present without any known risk
factors. Cazals-Hatem et al reported that no risk factors of INCPH were identified in 57% of patients with histologic OPV
with or without PH at presentation [40].
Metabolic factors
Given the broadened definitional spectrum of PSVD, liver

diseases that can cause pre-cirrhotic PH that are not included
in the “to be excluded” conditions of PSVD would meet the
diagnostic criteria of PSVD. The prime examples would be alcoholic fatty liver disease and NAFLD.
There is growing evidence that PH can occur in alcoholic
fatty liver disease and NAFLD even in the absence of significant fibrosis/cirrhosis and that it correlates with the degree
of steatosis [95-101]. Although the exact etiopathogenesis
remains unclear, multiple hypotheses have been proposed.
Enlarged and ballooned fatty hepatocytes impair portal blood
flow by narrowing the sinusoidal space. Consequent sinusoidal
endothelial cell injury and loss of fenestrations facilitate entrapment of blood cells with increased deposition of extracellular matrix in the space of Disse. Also, the endothelial cells’
inhibitory control on hepatic stellate cells diminishes leading
to unrestrained vasoconstriction, further impeding the sinusoidal blood flow. Resultant tissue hypoxia promotes inflammation, fibrosis and neovascularization by triggering Kupffer cell
activation [95].
Animal studies have also shown that steatohepatitis induces PH in the absence of fibrosis as a result of a hyperdynamic splanchnic circulation with increased portal blood flow
and impaired arteriolar response to vasoconstrictors [97, 102].
Similarly, Mendes et al found that obesity and diabetes are independently associated with the development of PH [102]. In
alcoholic liver disease, central sclerosing hyaline necrosis is
believed to be the contributory factor to the development of
pre-cirrhotic PH [101].
Likewise, Zuo et al found that individual morphologic INCPH/PSVD lesions were significantly more common in steatotic liver specimens when compared to incidental biopsies, in
the absence of PH [13]. This further corroborates the fact that
fatty liver disease may contribute to the vascular remodeling
seen in INCPH/PSVD though it will be difficult to determine
which component is the main driver accountable for the histologic changes (Fig. 3).
Etiopathogenic associations with PSVD are summarized
in Figure 4.
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Figure 4. Etiopathogenic associations with porto-sinusoidal vascular disease. #Systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Sjogren’s syndrome, inflammatory bowel diseases, celiac disease, autoimmune hepatitis, Felty’s syndrome.
¥Protein C or S deficiency, factor V Leiden, factor II mutation, antithrombin III deficiency. ±Antiphospholipid syndrome, malignancy, ADAMTS 13 deficiency, oral contraceptive use. *Turner syndrome, Adams-Oliver syndrome, cystic fibrosis, phosphomannose
isomerase deficiency. NAFLD: non-alcoholic fatty liver disease; HIV: human immunodeficiency virus.

Diagnosis
The diagnosis of INCPH/PSVD relies on a constellation of
clinical, radiologic and histologic findings. Liver biopsy is indispensable for documenting the absence of cirrhosis and as
previously stated, can establish the diagnosis by itself when
specific morphologic lesions of PSVD are identified [2].
Clinical presentation
Patients usually present with signs and symptoms of PH to include gastroesophageal (present in up to two-thirds of patients
at the time of diagnosis) and anorectal varices, hypersplenism
and thrombocytopenia [2, 80, 103]. Gastrointestinal bleeding
secondary to ruptured varices is the most frequently encountered presenting symptom seen in up to 50% of patients [80].
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There are 20-50% of patients presenting with ascites which often occurs in the setting of concurrent gastrointestinal infection
or hemorrhage. Some patients, however, may be completely
asymptomatic and signs of PH are discovered incidentally either by radiologic or endoscopic means [34]. Less commonly,
hepatic encephalopathy, hepatorenal and hepatopulmonary
syndrome may develop [2, 80]. Hepatic synthetic function is
relatively preserved, but progression to advanced hepatic insufficiency requiring liver transplantation occurs in 4-19% of
cases [40, 47, 104].
Subsequent portal vein thrombosis is frequently seen in
INCPH/PSVD patients. In a study by Matsutani et al, nine
(41%) of 22 patients with INCPH developed portal vein thrombosis after 12 years of follow-up, at a significantly higher incidence compared to cirrhotic patients. Also, the development
of portal vein thrombosis was an indicator of worse prognosis
[30]. Similarly, portal vein thrombosis developed in 75% of
INCPH patients with concurrent HIV infection after a median
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follow-up of 15 months [31].
As stated previously, clinical and or radiologic evidence
of PH is not a prerequisite for the diagnosis of PSVD. As such,
PSVD may be found during the workup of chronic abnormal
liver function tests of unknown etiology. Elevated serum levels of transaminases, alkaline phosphatase, gamma glutamyl
transferase and bilirubin have been variably reported. Not
uncommonly, patients may be referred to hematologists for
thrombocytopenia secondary to hypersplenism or abnormal
coagulation tests due to advanced liver dysfunction [79, 105].
However, PSVD may also be an incidental finding. For example, in a study by Lee et al, histologic features of INCPH
were identified in all liver biopsies from 13 dialysis patients
but only a third (four of 13) had underlying PH, qualifying for
INCPH [17]. Among the remaining nine patients without PH,
six (66%) would have met the diagnostic criteria for PSVD
given the presence of OPV in the liver specimens. Regardless,
the authors speculated that the findings of histologic features
of INCPH were reflective of the presence of known INCPH/
PSVD risk factors that are commonly encountered in this patient population. PSVD without PH was also reported as a
form of vascular remodeling in regressed fibrosis following
phlebotomy in hemochromatosis patients [14]. On the other
hand, some PSVD patients without PH at presentation may develop overt PH on follow-up studies [40, 79]. In Cazals-Hatem
et al’s study, six (40%) of 15 patients with OPV in liver specimens at presentation but without PH or portal vein thrombosis
developed PH after a mean follow-up of 8.6 years [40].
Radiologic features
Imaging studies can be used to document the presence of PH
either indirectly by noninvasive means (i.e., splenomegaly,
porto-systemic collaterals) or directly by measuring the hepatic venous pressures via catheterization of the hepatic veins.
They can also identify disease processes that should be otherwise excluded in order to diagnose PSVD (i.e., schistosomiasis, congenital hepatic fibrosis). Although radiologic findings
often lack sufficient specificity to establish a diagnosis, there
are some features that favor INCPH/PSVD.
First, combined hypertrophy of the caudate lobe and segment IV of the liver is suggestive of INCPH/PSVD whereas cirrhosis is usually associated with segment IV atrophy [41, 44].
Thickened hyperechoic walls of intrahepatic portal branches
on ultrasound and increased periportal signal intensity on T2weighted MRI can be seen in some INCPH/PSVD patients and
may represent periportal fibrosis [48, 53]. In addition, a normal or mildly elevated HVPG in the setting of overt stigmata
of PH would support the diagnosis of INCPH/PSVD as it is
indicative of a presinusoidal form of PH [32]. One caveat is
that the presence of intrahepatic vein-to-vein communications,
commonly seen in INCPH/PSVD, precludes an adequate assessment of HVPG and subsequently would underestimate the
actual value of the portal venous pressure [32, 106]. Also, it is
important to note that even though preserved liver volume and
the absence of nodular contours would favor INCPH/PSVD in
the early stages of the disease [48], hepatic surface nodularity resembling cirrhosis can be seen in INCPH/PSVD [10, 55]

Figure 5. Magnetic resonance imaging with contrast shows mild nodular contour of the liver surface (arrows) and relative hypertrophy of the
caudate lobe (*) in porto-sinusoidal vascular disease.

(Fig. 5). Abnormalities of the intrahepatic portal venous system (i.e., reduced caliber, diminished visibility and occlusive
thrombosis) are more commonly seen in INCPH/PSVD than
in cirrhosis [41].
Data on liver stiffness measurement (via transient elastography) are limited in INCPH/PSVD. However, recent studies have shown that it can be useful in distinguishing INCPH/
PSVD from cirrhosis [32, 33, 107]. INCPH/PSVD has significantly lower mean liver stiffness compared to that of cirrhosis.
In Elkrief et al’s study, the cutoff values of 10 and 20 kPa were
found to have sufficient sensitivity and specificity, respectively, in distinguishing the two [107]. For example, liver stiffness
values lower than 10 kPa were highly suggestive of INCPH/
PSVD in patients with signs of PH whereas levels exceeding
20 kPa effectively excluded the disease [107]. Additionally,
hepatic venography shows frequent veno-venous shunts in INCPH/PSVD with narrower angles between the large veins and
their branches when compared to cirrhosis [108].
Histomorphologic findings
INCPH/PSVD lesions can be observed both in the portal tracts
and within hepatic lobules. The definition of PSVD identifies
three specific histologic lesions that are sufficient, per se, to
establish the diagnosis even in the absence of clinical or radiologic features of PH: OPV, nodular regenerative hyperplasia
and incomplete septal fibrosis/cirrhosis [2] (Table 2).
OPV, also known as phlebosclerosis [38], is considered
to be the hallmark of PSVD. It is believed to be the initiating
event leading to increased portal flow resistance and sustained
presinusoidal hypertension [79]. OPV is characterized by mural fibrosis and thickening of intrahepatic small and mediumsized portal vein branches with subsequent luminal narrowing,
obliteration and venopenia [12, 42]. However, it is important
to distinguish these features from portal dyads, a normal histologic variant, where the lack of portal veins may be misinterpreted as OPV [13].
Nodular regenerative hyperplasia was first introduced by
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Figure 6. (a) Obliterative portal venopathy (also known as phlebosclerosis) with inconspicuous portal venous branch (arrow)
(hematoxylin and eosin, × 200). (b) Incomplete septal fibrosis or cirrhosis (Masson-trichrome, × 150). (c) Nodular regenerative
hyperplasia. The nodularity is highlighted by reticulin special stain (reticulin, × 30). (d) Trichrome stain shows the absence of cirrhosis in nodular regenerative hyperplasia (Masson-trichrome, × 30).

Steinert as a liver parenchymal micronodularity in the absence
of fibrosis [60]. It appears to be the result of OPV with subsequent uneven perfusion of the liver parenchyma. The nodules
are usually small (1 - 3 mm), ill-defined and composed of the
hyperplastic central zones delineated by peripherally compressed atrophic hepatic cell plates. The nodular architecture
is better appreciated with a reticulin stain that highlights the
condensed reticulin network at the periphery of the nodules
[61, 79]. Cytokeratin 7 immunostain may also be helpful as it
is often expressed in atrophic hepatocytes [109].
Incomplete septal fibrosis/cirrhosis is characterized by the
presence of thin fibrous septae emanating from a portal tract
and ending blindly within the hepatic lobule [79]. Although a
vague and poorly demarcated hepatic nodularity can be seen,
complete cirrhotic-type nodules should not be seen in incomplete septal fibrosis/cirrhosis (Fig. 6).
PSVD scheme defines not specific histologic lesions as
those that can be associated with INCPH/PSVD but lack specificity. These include portal tract abnormalities such as aberrant
vessels (i.e., periportal shunting vessels, herniated portal veins
branches, multiplicity of portal vessels within a single portal
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tract, dilatation of arteries), irregular distribution of the portal
tracts and central veins, non-zonal sinusoidal dilatation and
mild perisinusoidal fibrosis [2] (Table 2). Additionally, portal
tract remnants (defined as portal tract smaller than twice the
size of a bile duct) are frequently seen in INCPH/PSVD [9,
13, 14, 18, 79].
The most common lobular abnormality seen in INCPH/
PSVD is sinusoidal dilatation [1, 12, 40, 42, 79] as INCPH/
PSVD is a form of vascular pattern injury. However, sinusoidal dilatation is not specific and can be associated with other
vascular, neoplastic, inflammatory, infectious and medicationrelated etiologies [77]. It is important to note that in INCPH/
PSVD, sinusoidal dilatation is random and non-zonal [2],
whereas it is predominantly centrilobular when associated
with usual etiogenic factors and mainly periportal when associated with oral contraceptive use [71]. Interestingly, a recent reproducibility study on individual histologic features of
INCPH/PSVD has shown that the recognition of sinusoidal
dilatation was relatively reproducible amongst nine experienced liver pathologists, although the zone in which sinusoidal
dilatation was identified was not specified. This indicates that
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Figure 7. (a) Paraportal shunt vessel (arrow) in idiopathic non-cirrhotic portal hypertension/porto-sinusoidal vascular disease
(INCPH/PSVD) (hematoxylin and eosin (H&E), × 200). (b) Irregularly distributed portal tracts and central veins in INCPH/PSVD.
Non-zonal sinusoidal dilatation is also noted (H&E, × 50). (c) Mild perisinusoidal fibrosis (Masson-trichrome, × 130). (d) Rudimentary portal tract in INCPH/PSVD (H&E, × 250).

recognizing sinusoidal dilatation may be a helpful clue in considering the diagnosis of INCPH/PSVD in the right clinical
context [18] (Fig. 7).
In an attempt to standardize the variable terminologies
used for these histologic lesions, specifically for INCPH, the
International Liver Pathology Study Group proposed “portal
vein stenosis” for phlebosclerosis and OPV, “herniated portal
vein” for herniated portal vein branches, “hypervascularized
portal tract” for multiplicity of portal vessels and “periportal
abnormal vessels” for periportal shunting vessels [11].
Interobserver variability
Histologic lesions of INCPH/PSVD are heterogenous and frequently overlap with other entities thus, display low interobserver agreement even among experienced liver pathologists
[18, 66, 110]. Liang et al recently have shown that the interobserver agreement can be improved when OPV is recognized as
the sole independent predictor of INCPH/PSVD. Further, the
authors proposed three different categories for OPV: consistent
with OPV, indeterminate for OPV and not consistent with OPV
[110]. Whether this novel categorization improves diagnostic
accuracy of INCPH/PSVD is yet to be determined and needs
to be validated by future studies.
Inflow vs. outflow vascular abnormality
INCPH/PSVD is a presinusoidal form of PH thus falls within
the spectrum of inflow vascular abnormality. Another cardinal
example of inflow vascular abnormality with similar clinical

and morphologic pictures is chronic non-cirrhotic, non-malignant portal vein thrombosis [73]. Therefore, despite overlapping clinical and morphologic features, INCPH/PSVD should
be distinguished from hepatic venous outflow abnormality.
Histologic hallmark of INCPH/PSVD is OPV in the portal
tracts and other vascular and parenchymal changes are considered secondary to OPV [2]. In contrast, in outflow vascular
abnormality (as in BCS, SOS and congestive hepatopathy), the
morphologic changes predominate in the central zones (congestion, necrosis and eventual fibrosis) and affect the central
veins [73, 105]. Additionally, despite similar presenting symptoms, the clinicoradiologic context would be quite different
between inflow and outflow abnormality. For example, the
presence of heart failure in congestive hepatopathy, history of
hematopoietic stem cell transplantation and drug exposure in
SOS and radiologic evidence of hepatic venous outflow obstruction in BCS would essentially preclude the diagnosis of
INCPH/PSVD. However, in a limited sample or advanced diseases, determining primary lesion (portal tract vs. lobule) can
be challenging.
Diagram summarizing the diagnostic approach for INCPH
and PSVD is illustrated in Figure 8.

Management
There is no specific treatment for PSVD, especially in patients
without PH as some of these patients may probably never develop overt PH. In fact, the natural history of PSVD in the
absence of PH is largely unknown [2] and large-scale prospective studies are needed in order to implement management recommendations in this patient population. Currently, the initial
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Figure 8. Diagram summarizing the diagnostic approach for idiopathic non-cirrhotic portal hypertension and porto-sinusoidal
vascular disease. *Portal vein thrombosis may be seen along the natural disease course of idiopathic non-cirrhotic portal hypertension. #Biopsy adequacy criteria are available for porto-sinusoidal vascular disease (core liver biopsy ≥ 20 mm in length or
featuring ≥ 10 portal tracts, or when considered adequate by an expert pathologist).

management for patients with INCPH and PSVD with PH is
to identify and treat the underlying conditions known to be associated with the disease [10].
In INCPH, complications related to PH are managed in a
similar fashion with those in patients with cirrhotic PH [10,
80]. These patients should be screened regularly for gastroesophageal varices and prophylactic measures for variceal
bleeding should be implemented when varices are identified.
Regarding the timing of endoscopic follow-up and the type of
prophylaxis recommended in INCPH, the few studies available failed to draw solid conclusions as only a small number of
patients were studied [111, 112]. Therefore, in the absence of
specific and universally implemented guidelines, the screening frequency and primary and secondary prophylaxis for variceal bleeding in INCPH are similar to those recommended
for cirrhotic PH. The prophylactic measures include the use of
non-specific beta-adrenergic blockage and endoscopic band
ligation [2, 56, 80, 113]. Similarly, the management for ascites
and hepatic encephalopathy is identical to those in cirrhotic patients. Transjugular intrahepatic porto-systemic shunt
(TIPS) is reserved for patients with severe variceal bleeding
and refractory ascites who fail conservative treatment. An
international multicenter study showed that the outcomes of
TIPS were favorable with a 2-year survival rate of 80% in
INCPH patients [114].
Treatment with anticoagulants is often considered in INCPH given the frequent association with portal vein thrombosis and underlying hypercoagulable state. However, routine
use of anticoagulants in INCPH patients is currently not recommended due to insufficient evidence of benefit [113, 115].
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On the other hand, current guidelines recommend biannual
Doppler ultrasound in INCPH/PSVD patients for early detection of portal vein thrombosis [115]. Liver transplantation is a
valid option for INCPH patients with advanced hepatocellular
insufficiency. The data regarding outcomes after liver transplantation in INCPH patients are limited, but appear overall
favorable [6, 62].

Clinical Outcomes
In general, INCPH/PSVD patients fare considerably better
than those with cirrhosis. Patients with INCPH/PSVD are less
likely to develop ascites or hepatic encephalopathy than cirrhosis patients. Even though variceal bleeding is more common, the associated mortality is significantly lower compared
to cirrhosis patients [34, 54]. This might be due to relatively
preserved hepatocellular function in INCPH/PSVD [10].
Recent study has shown that the clinical course of PSVD
without PH is more favorable than that of INCPH/PSVD with
PH. Woran et al compared PSVD patients with PH (INCPH)
to PSVD patients without PH and found the former to have
higher Child-Pughes scores, higher prevalence of liver decompensation and higher liver-related mortality compared to the
latter [116].
Progression toward advanced hepatic failure and the development of hepatocellular carcinoma are unusual in INCPH/PSVD [104, 117, 118]. Hence, routine ultrasonographic
screening for hepatocellular carcinoma is generally not recommended in INCPH/PSVD patients [80].
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Summary
In summary, INCPH/PSVD remains relatively under-recognized and its incidence is probably underestimated. INCPH
can be diagnosed when histologic features of INCPH/PSVD
are identified in a non-cirrhotic liver biopsy from patients
with PH of unknown etiology. Minimum histologic diagnostic
criteria are not defined in INCPH. On the other hand, PSVD
may be diagnosed in the absence of PH when aforementioned
specific histologic features are present on liver biopsy. When
not specific histologic features are only present, certain clinical signs of PH are required to establish a diagnosis of PSVD.
Future studies and investigations are needed in order to better
define the significance of subclinical PSVD and to standardize
diagnostic and therapeutic strategies. Although we acknowledge that PSVD is a broader term, given the importance of
PH in patients’ management, the term INCPH might be a better choice than PSVD with PH. The term PSVD without PH
would be a reasonable histologic diagnosis that can be used to
accrue relevant clinical data.
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